Cancer Treatment Waits Have Grown by More Than 10 Days Over Past Decade

A major study of 2.7 million patients reveals alarming delays in care that have stretched across all major cancer types, raising concerns about outcomes.

By Duabbly Staff

The time patients spend waiting between receiving a cancer diagnosis and beginning treatment has stretched considerably over the past decade, according to a comprehensive analysis published in JAMA Surgery. The finding underscores a growing bottleneck in the American healthcare system that experts say demands urgent attention.

Researchers from UCLA and Massachusetts General Hospital examined national data spanning from January 2012 through December 2023, tracking the treatment timelines of more than 2.7 million patients diagnosed with six of the most common cancer types. The study population included adults with early to locally advanced stages of breast, colon, lung, pancreatic, stomach, and esophageal cancer who underwent surgery as a core component of their initial treatment approach.

The numbers paint a troubling picture across nearly every cancer type examined. Stomach cancer patients experienced the most dramatic increase in wait times, with median delays jumping from 35 days at the study's outset to 49 days by 2023. Lung cancer saw similarly substantial growth, rising from 41 days to 53 days. Breast cancer treatment delays climbed from 34 days to 45 days, while colon cancer patients waited an additional 11 days compared to the starting point, moving from 20 to 31 days. Those diagnosed with pancreatic cancer saw waits increase from 23 to 32 days, and esophageal cancer patients experienced delays growing from 38 to 48 days.

The research team measured these intervals starting from the moment of diagnosis and extending through the beginning of treatment, whether that constituted surgery or pre-operative therapy designed to reduce tumor size. The consistency of the pattern across different cancer types and treatment approaches suggests the delays reflect systemic issues rather than isolated problems affecting particular patient populations or facilities.

Additionally troubling is what the data reveals about longer delays. The proportion of patients forced to wait 60 days or more before initiating treatment has been climbing throughout the study period, indicating that extreme wait times are becoming more prevalent rather than remaining exceptional circumstances.

Dr. Marc Siegel, who serves as a senior medical analyst but was not involved in the research, characterized the findings as reflective of a healthcare system component requiring immediate reform. He emphasized that even prestigious high-volume academic medical centers, which typically possess more resources and personnel than community facilities, have not been immune to these lengthening timelines. The delays in initiating treatment for non-metastatic cancers represent a particularly concerning trend given the potential implications for patient outcomes.

The researchers conducted their analysis using data from the National Cancer Database, one of the most comprehensive sources of cancer incidence and treatment information available in the United States. After accounting for variables including patient age and existing health conditions, they found that the delays occurred consistently across different demographic groups.

The implications of these delays extend beyond mere inconvenience. In oncology, timing frequently matters significantly for treatment effectiveness and prognosis. Extended waits between diagnosis and intervention can allow disease progression, potentially affecting whether tumors remain operable or responsive to initial planned therapies. The psychological burden on newly diagnosed patients awaiting care also represents a meaningful healthcare concern.

The factors contributing to these expanding timelines likely stem from multiple sources within the healthcare infrastructure. Capacity constraints, staffing limitations, scheduling complexities, and administrative hurdles all potentially play roles. The pandemic and its aftermath may have compounded some facility-level challenges, though the trends began well before COVID-19 emerged.

The study's decade-long timeframe provides substantial evidence that these delays represent a persistent and worsening pattern rather than temporary fluctuations. The consistent increases across six different cancer types suggest the problem reflects broader system dysfunction rather than challenges specific to particular disease categories or treatment modalities.

Cancer advocacy groups and healthcare policy experts have increasingly flagged treatment delays as a quality and equity concern. Disparities in access to timely care can correlate with disparities in outcomes, raising questions about whether all patient populations experience similar wait times or whether certain geographic areas, socioeconomic groups, or insurance categories face particular barriers.

The findings arrive amid broader discussions about cancer care capacity, workforce adequacy in oncology, and healthcare system resource allocation. As cancer incidence continues rising due to demographic shifts and other factors, the ability to deliver timely care becomes an increasingly pressing challenge. The research suggests that current capacity has not kept pace with demand, creating growing bottlenecks that may ultimately affect patient survival rates and quality of life outcomes for millions of Americans navigating diagnosis and treatment.